Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(0.36) per share which met the analyst consensus estimate. This is a 44 percent decrease over losses of $(0.25) per share from the same period last year.
RBC Capital Downgrades Neurocrine Biosciences to Sector Perform, Lowers Price Target to $90
RBC Capital analyst Brian Abrahams downgrades Neurocrine Biosciences (NASDAQ:NBIX) from Outperform to Sector Perform and lowers the price target from $122 to $90.
